MedPath

Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis

Phase 2
Completed
Conditions
Lupus Nephritis
Interventions
Drug: BI 655064 dose 1
Drug: BI 655064 dose 2
Drug: BI 655064 dose 3
Drug: Placebo
Registration Number
NCT02770170
Lead Sponsor
Boehringer Ingelheim
Brief Summary

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
121
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BI 655064 dose 1BI 655064 dose 1-
BI 655064 dose 2BI 655064 dose 2-
BI 655064 dose 3BI 655064 dose 3-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Percentage of Patients With Complete Renal Response (CRR) at Week 52At week 52.

Complete renal response (CRR) was defined as urine protein (UP) \< 0.5 g/day at Week 52 and either estimated glomerular filtration rate (eGFR) within normal range at Week 52 or decrease in eGFR \< 20% from baseline at Week 52 if eGFR was below normal range (below lower limit of normal \[LLN\], where LLN = 90 mL/min).

CRR at Week 52 (derived using UP from the 24 h urine collections) was analyzed using a logistic regression model. Factors in the model included treatment and the covariates race (Asian/Non-Asian) and proteinuria at screening (UP/urine creatinine (UC) \<3 or \>=3 g/day).

Pairwise comparisons of the modelled proportions of patients with CRR at each dose level to placebo were performed.

Secondary Outcome Measures
NameTimeMethod
Percentage of Patients With Partial Renal Response (PRR) at Week 52At week 52.

Partial renal response (PRR) was defined as at least 50% reduction of proteinuria from baseline if estimated glomerular filtration rate (eGFR) was within normal range at time of assessment or decrease of eGFR \<20% from baseline if eGFR was below normal range at time of assessment.

Percentage of Patients With Complete Renal Response (CRR) at Week 26At week 26.

Complete renal response (CRR) was defined as urine protein (UP) \< 0.5 g/day at Week 26 and either estimated glomerular filtration rate (eGFR) within normal range at Week 26 or decrease in eGFR \< 20% from baseline at Week 26 if eGFR was below normal range (below lower limit of normal \[LLN\], where LLN = 90 mL/min).

Percentage of Patients With Partial Renal Response (PRR) at Week 26At week 26.

Partial renal response (PRR) was defined as at least 50% reduction of proteinuria from baseline if estimated glomerular filtration rate (eGFR) was within normal range at time of assessment or decrease of eGFR \<20% from baseline if eGFR was below normal range at time of assessment.

Percentage of Patients With Major Renal Response (MRR) at Week 26At week 26.

Major renal response was defined as follows depending on proteinuria at baseline:

* If baseline proteinuria was \<3 g/day and patient had complete renal response (CRR)

* If baseline proteinuria was \>= 3 g/day and proteinuria \< 1 g/day and either estimated glomerular filtration rate (eGFR) within normal range or decrease in eGFR \<20% from baseline at Week 26 if eGFR was below normal range (below lower limit of normal (LLN), where LLN = 90 mL/min)

Percentage of Patients With Major Renal Response (MRR) at Week 52At week 52.

Major renal response was defined as follows depending on proteinuria at baseline:

* If baseline proteinuria was \<3 g/day and patient had complete renal response (CRR)

* If baseline proteinuria was \>= 3 g/day and proteinuria \< 1 g/day and either estimated glomerular filtration rate (eGFR) within normal range or decrease in eGFR \<20% from baseline at Week 52 if eGFR was below normal range (below lower limit of normal (LLN), where LLN = 90 mL/min)

Trial Locations

Locations (74)

Feinstein Institute for Medical Research

🇺🇸

Manhasset, New York, United States

Hospital Curry Cabral, EPE

🇵🇹

Lisboa, Portugal

Institute of Rheumatology, Belgrade

🇷🇸

Belgrade, Serbia

Pramongkutklao Hospital

🇹🇭

Bangkok, Thailand

University General Hospital Attikon

🇬🇷

Athens, Greece

Leicester General Hospital

🇬🇧

Leicester, United Kingdom

Integrity Clinical Research, LLC

🇺🇸

Doral, Florida, United States

Office of Dr. Ramesh C. Gupta

🇺🇸

Memphis, Tennessee, United States

Columbia University Medical Center-New York Presbyterian Hospital

🇺🇸

New York, New York, United States

Integral Rheumatology and Immunology Specialist

🇺🇸

Plantation, Florida, United States

Toronto Western Hospital

🇨🇦

Toronto, Ontario, Canada

Hope Clinical Research

🇺🇸

Kissimmee, Florida, United States

CHU de Quebec-Universite Laval Research Centre

🇨🇦

Quebec, Canada

The Prince of Wales Hospital

🇦🇺

Randwick, New South Wales, Australia

Universitätsklinikum Schleswig-Holstein, Campus Lübeck

🇩🇪

Lübeck, Germany

Academic Medical Research Institute

🇺🇸

Los Angeles, California, United States

Princess Alexandra Hospital

🇦🇺

Woolloongabba, Australia

Universitätsklinikum Köln (AöR)

🇩🇪

Köln, Germany

HOP Henri Mondor

🇫🇷

Creteil, France

Robert-Bosch-Krankenhaus GmbH

🇩🇪

Stuttgart, Germany

Hospital of the University of Occupational and Environmental Health

🇯🇵

Fukuoka, Kitakyushu, Japan

St. Marianna University School of Medicine Hospital

🇯🇵

Kanagawa, Kawasaki, Japan

Instituto Nacional de Cs Médicas y Nutrición S Zubiran

🇲🇽

Ciudad de Mexico, Mexico

Military Medical Academy

🇷🇸

Belgrade, Serbia

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

Emory University

🇺🇸

Atlanta, Georgia, United States

Northwell Health

🇺🇸

Great Neck, New York, United States

General University Hospital Prague 2, Nephrology Clinic

🇨🇿

Prague, Czechia

Asklepios Klinik Altona

🇩🇪

Hamburg, Germany

Hospital Hradec Kralove

🇨🇿

Hradec Kralove, Czechia

Institute of Rheumathology Prague

🇨🇿

Prague, Czechia

HOP La Pitié Salpêtrière

🇫🇷

Paris, France

Universitätsmedizin Göttingen, Georg-August-Universität

🇩🇪

Göttingen, Germany

General Hospital of Athens "Laiko"

🇬🇷

Athens, Greece

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

🇩🇪

Mainz, Germany

University General Hospital of Heraklion

🇬🇷

Heraklion, Crete, Greece

Queen Mary Hospital

🇭🇰

Hong Kong, Hong Kong

Azienda Ospedaliera Universitaria di Padova

🇮🇹

Padova, Italy

Tohoku University Hospital

🇯🇵

Miyagi, Sendai, Japan

Okayama University Hospital

🇯🇵

Okayama, Okayama, Japan

Juntendo University Hospital

🇯🇵

Tokyo, Bunkyo-ku, Japan

Hokkaido University Hospital

🇯🇵

Hokkaido, Sapporo, Japan

Ajou University Hospital

🇰🇷

Suwon, Korea, Republic of

Keio University Hospital

🇯🇵

Tokyo, Shinjuku-ku, Japan

Instituto Nacional de Cardiologia Ignacio Chavez

🇲🇽

Ciudad de Mexico, Mexico

H. Central Dr Ignacio M. P.

🇲🇽

San Luis Potosi, Mexico

Angeles University Foundation Medical Center

🇵🇭

Angeles City, Philippines

Cebu Doctors Hospital

🇵🇭

Cebu City, Cebu, Philippines

Southern Philippines Medical Center

🇵🇭

Davao, Philippines

Norbert Barlicki University Clinical Hospital No.1, Lodz

🇵🇱

Lodz, Poland

Clinic Medical Center; Nowa Sol

🇵🇱

Nowa Sol, Poland

NZOZ Centrum Medyczne AESKULAP,Private Prac, Radom

🇵🇱

Radom, Poland

John Paul II Regional Hospital, Zamosc

🇵🇱

Zamosc, Poland

CHULN, EPE - Hospital de Santa Maria

🇵🇹

Lisboa, Portugal

Centro Hospitalar Universitário São João,EPE

🇵🇹

Porto, Portugal

Hospital Vall d'Hebron

🇪🇸

Barcelona, Spain

Clinical Centre Nis

🇷🇸

Nis, Serbia

Fundación Jiménez Díaz

🇪🇸

Madrid, Spain

Hospital Dr. Peset

🇪🇸

Valencia, Spain

Chiangmai University

🇹🇭

Chiangmai, Thailand

Naresuan University Hospital

🇹🇭

Muang, Thailand

Addenbrooke's Hospital

🇬🇧

Cambridge, United Kingdom

Hospital Raja Permaisuri Bainun

🇲🇾

Ipoh, Malaysia

Hospital Cardiologica Aguascalientes

🇲🇽

Aguascalientes, Mexico

Cent.Clin.Hosp.Med.Univ.Lodz,Electrocard

🇵🇱

Lodz, Poland

Chong Hua Hospital

🇵🇭

Cebu City, Philippines

CHUC - Centro Hospitalar e Universitário de Coimbra, EPE

🇵🇹

Coimbra, Portugal

University Clinical Hospital in Bialystok I

🇵🇱

Bialystok, Poland

King Chulalongkorn Memorial Hospital

🇹🇭

Bangkok, Thailand

Siriraj Hospital

🇹🇭

Bangkok, Thailand

Hospital Tengku Ampuan Rahimah

🇲🇾

Klang, Malaysia

Mary Mediatrix Medical Center

🇵🇭

Lipa City, Batangas, Philippines

Guy's Hospital

🇬🇧

London, United Kingdom

Prince of Wales Hospital

🇭🇰

HK, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath